WO2003090675A3 - Methods and compositions useful for treating prostate cancer - Google Patents

Methods and compositions useful for treating prostate cancer Download PDF

Info

Publication number
WO2003090675A3
WO2003090675A3 PCT/US2003/012392 US0312392W WO03090675A3 WO 2003090675 A3 WO2003090675 A3 WO 2003090675A3 US 0312392 W US0312392 W US 0312392W WO 03090675 A3 WO03090675 A3 WO 03090675A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prostate cancer
compositions useful
treating prostate
immunopeptides
Prior art date
Application number
PCT/US2003/012392
Other languages
French (fr)
Other versions
WO2003090675A2 (en
Inventor
Richard A Lerner
Alan Saven
Original Assignee
Scripps Research Inst
Richard A Lerner
Alan Saven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Richard A Lerner, Alan Saven filed Critical Scripps Research Inst
Priority to AU2003237093A priority Critical patent/AU2003237093A1/en
Publication of WO2003090675A2 publication Critical patent/WO2003090675A2/en
Publication of WO2003090675A3 publication Critical patent/WO2003090675A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Immunopeptides are provided that are composed of a prostate specific antigen (PSA) coupled to an autoimmune tag, or a prostate specific polypeptide (PSP) coupled to an autoimmune tag. Pharmaceutical compositions containing the immunopeptides are provided. Methods to treat prostate cancer are also provided. Antibodies to the immunopeptides are provided.
PCT/US2003/012392 2002-04-25 2003-04-21 Methods and compositions useful for treating prostate cancer WO2003090675A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003237093A AU2003237093A1 (en) 2002-04-25 2003-04-21 Methods and compositions useful for treating prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37595802P 2002-04-25 2002-04-25
US60/375,958 2002-04-25

Publications (2)

Publication Number Publication Date
WO2003090675A2 WO2003090675A2 (en) 2003-11-06
WO2003090675A3 true WO2003090675A3 (en) 2006-06-01

Family

ID=29270734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/012392 WO2003090675A2 (en) 2002-04-25 2003-04-21 Methods and compositions useful for treating prostate cancer

Country Status (2)

Country Link
AU (1) AU2003237093A1 (en)
WO (1) WO2003090675A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PRIGOZHINA ET AL: "Autoimmune-response induction and regulation in rat erythrocyte-immunized mice.", IMMONOLOGY LETTERS., vol. 30, no. 3, 1991, pages 283 - 290, XP023691503, DOI: doi:10.1016/0165-2478(91)90039-D *
WEIGLE.: "The induction of autoimmunity in rabbits following injection of heterologous or altered homologous thyroglobulin.", J EXP MED., vol. 121, 1965, pages 289 - 308 *
WILLIS ET AL: "A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).", INTL J MOL MED., vol. 1, no. 2, February 1998 (1998-02-01), pages 379 - 386 *

Also Published As

Publication number Publication date
AU2003237093A8 (en) 2003-11-10
AU2003237093A1 (en) 2003-11-10
WO2003090675A2 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
EP2345671B8 (en) Optimized fc variants and methods for their generation
AU2003278002A1 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
AU2003264068A1 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004035603A3 (en) Erythropoietin receptor binding antibodies
TW200510459A (en) RG1 antibodies and uses thereof
WO2004050707A3 (en) Tumor-specific recognition molecules
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
AU2003224076A1 (en) Antibody combination useful for tumor therapy
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
AU2003302165A8 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2004029214A3 (en) Lfa-1 alpha subunit antibodies and methods of use
AU2003215381A1 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
AU2002351374A1 (en) Antibodies to treat cancer
WO2003090675A3 (en) Methods and compositions useful for treating prostate cancer
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
AU1700700A (en) Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
AU2003268180A1 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
AU2002258437A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP